Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a $15 price target after removing pulmonary arterial hypertension and obesity programs from the firm’s model.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler
- Keros Therapeutics price target lowered to $41 from $44 at Scotiabank
- Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer
- Keros Therapeutics price target lowered to $32 from $33 at BofA
- Big banks report Q4 beats, QXO proposes to buy Beacon: Morning Buzz